Sepsis is a deadly disease that is widely attributed to endotoxin released by gram‐negative bacterial infections often plague emergency care facilities. Conventionally antibiotics and vasopressors are used to treat this disease. Recent treatment protocol shifted to a membrane to remove the offending endotoxin monomer. Despite this shift, membrane‐based devices are often extremely costly, hindering accessibility to this life saving medical device. In view of this challenges, we adopted the internally developed polysulfone (PSF) microtube array membrane alternating (MTAM‐A) for use in blood sepsis treatment. PSF MTAM‐A were with polymyxin B (PMB) molecules immobilized were assembled into an internally developed cartridge housing and subjected to endotoxin removal models with water and blood spiked with 100 EU/ml of endotoxin as the feed solution. Samples were derived at 15, 30, 60, and 120 min and endotoxin levels were determined with limulus amebocyte lysate assay and benchmarked against the commercially available Toraymyxin device. The PSF MTAM‐A with 2.3 times the surface area was successfully fabricated and with PMB molecules immobilized, and assembled into a hemoperfusion device. Dynamic endotoxin removal test revealed and overall endotoxin removal capacity of 90% and a superior endotoxin removal efficiency that was significantly higher than that of Toraymyxin (internally conducted and reported). The data suggested that PSF MTAM‐A PMB membranes could potentially be applied in future hemoperfusion devices which would be significantly more efficient, compact, and affordable; potentially making such a life‐saving medical device widely available to the general public.

中文翻译：

---

超高堆积密度下一代微管阵列膜：一种基于吸收的体外内毒素去除装置的新解决方案。

脓毒症是一种致命的疾病，广泛归因于革兰氏阴性细菌感染释放的内毒素，常常困扰着急诊机构。通常使用抗生素和血管加压药来治疗这种疾病。最近的治疗方案转向使用膜去除有害的内毒素单体。尽管有这种转变，但基于膜的设备通常非常昂贵，阻碍了这种救生医疗设备的可及性。鉴于这一挑战，我们采用了内部开发的聚砜（PSF）微管阵列膜交替（MTAM-A）用于血液脓毒症治疗。PSF MTAM-A 与固定的多粘菌素 B (PMB) 分子组装到内部开发的滤芯外壳中，并进行内毒素去除模型，水和血液中加入 100 EU/ml 内毒素作为进料溶液。样品在 15、30、60 和 120 分钟后得到，内毒素水平用鲎变形细胞裂解物测定法测定，并以市售 Toraymyxin 装置为基准。成功制造了表面积为 2.3 倍的 PSF MTAM-A，并固定了 PMB 分子，并组装成血液灌流装置。动态内毒素去除试验显示，整体内毒素去除能力达90%，内毒素去除效率明显高于东丽粘菌素（内部进行和报道）。数据表明，PSF MTAM-A PMB 膜有可能应用于未来的血液灌流设备，这些设备将显着提高效率、紧凑性和经济性；有可能使这种拯救生命的医疗设备广泛提供给公众。